Abnormal islet sphingolipid metabolism in type 1 diabetes

Research output: Contribution to journalJournal articleResearchpeer-review


  • Laurits J. Holm
  • Lars Krogvold
  • Hasselby, Jane Preuss
  • Simranjeet Kaur
  • Laura A. Claessens
  • Mark A. Russell
  • Clayton E. Mathews
  • Kristian F. Hanssen
  • Noel G. Morgan
  • Bobby P.C. Koeleman
  • Bart O. Roep
  • Ivan C. Gerling
  • Pociot, Flemming
  • Knut Dahl-Jørgensen
  • Karsten Buschard

Aims/hypothesis: Sphingolipids play important roles in beta cell physiology, by regulating proinsulin folding and insulin secretion and in controlling apoptosis, as studied in animal models and cell cultures. Here we investigate whether sphingolipid metabolism may contribute to the pathogenesis of human type 1 diabetes and whether increasing the levels of the sphingolipid sulfatide would prevent models of diabetes in NOD mice. Methods: We examined the amount and distribution of sulfatide in human pancreatic islets by immunohistochemistry, immunofluorescence and electron microscopy. Transcriptional analysis was used to evaluate expression of sphingolipid-related genes in isolated human islets. Genome-wide association studies (GWAS) and a T cell proliferation assay were used to identify type 1 diabetes related polymorphisms and test how these affect cellular islet autoimmunity. Finally, we treated NOD mice with fenofibrate, a known activator of sulfatide biosynthesis, to evaluate the effect on experimental autoimmune diabetes development. Results: We found reduced amounts of sulfatide, 23% of the levels in control participants, in pancreatic islets of individuals with newly diagnosed type 1 diabetes, which were associated with reduced expression of enzymes involved in sphingolipid metabolism. Next, we discovered eight gene polymorphisms (ORMDL3, SPHK2, B4GALNT1, SLC1A5, GALC, PPARD, PPARG and B4GALT1) involved in sphingolipid metabolism that contribute to the genetic predisposition to type 1 diabetes. These gene polymorphisms correlated with the degree of cellular islet autoimmunity in a cohort of individuals with type 1 diabetes. Finally, using fenofibrate, which activates sulfatide biosynthesis, we completely prevented diabetes in NOD mice and even reversed the disease in half of otherwise diabetic animals. Conclusions/interpretation: These results indicate that islet sphingolipid metabolism is abnormal in type 1 diabetes and suggest that modulation may represent a novel therapeutic approach. Data availability: The RNA expression data is available online at https://www.dropbox.com/s/93mk5tzl5fdyo6b/Abnormal%20islet%20sphingolipid%20metabolism%20in%20type%201%20diabetes%2C%20RNA%20expression.xlsx?dl=0. A list of SNPs identified is available at https://www.dropbox.com/s/yfojma9xanpp2ju/Abnormal%20islet%20sphingolipid%20metabolism%20in%20type%201%20diabetes%20SNP.xlsx?dl=0.

Original languageEnglish
Issue number7
Pages (from-to)1650-1661
Number of pages12
Publication statusPublished - 2018

    Research areas

  • Fenofibrate, Gene polymorphisms, GWAS, Islet autoimmunity, NOD mice, Prevention, Sphingolipid, Sulfatide, T cells, Type 1 diabetes

Number of downloads are based on statistics from Google Scholar and www.ku.dk

No data available

ID: 213921419